Close Menu
Home › NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

Dec 06, 2016
|
staff reporter

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.

Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. Employee Benefits Programs Share Early Experiences Implementing Genetic Testing

    Premium

  2. HTG Molecular Diagnostics Files for $20M Stock Offering

  3. FDA Clears NantHealth Tumor-Normal Whole-Exome Test

  4. Exact Sciences Sues Johns Hopkins University for 'Improperly' Demanding Royalties

  5. AMP Attendees Reflect on Uptake of Tumor Mutational Burden Amid Validation, Utility Questions

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.